Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma
Authors
- Yiqin Weng
- Chunde Bao
- Hua‐Wei Jiang (ORCID: https://orcid.org/0000-0001-8970-3770)
- Xibin Xiao
- Xian Li (ORCID: https://orcid.org/0000-0002-9526-9031)
- Wenbin Qian (ORCID: https://orcid.org/0000-0002-6138-5616)
- Jing Xie (ORCID: https://orcid.org/0000-0001-6113-1336)
Institutions
- Ningbo No. 2 Hospital (CN)
- Ningbo University Affiliated Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Investigational New Drugs
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1007/s10637-025-01548-1
- Citations
- 1
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.39